扩张
发表于 2025-3-27 01:01:36
http://reply.papertrans.cn/83/8209/820888/820888_31.png
reperfusion
发表于 2025-3-27 01:33:44
http://reply.papertrans.cn/83/8209/820888/820888_32.png
不给啤
发表于 2025-3-27 07:21:41
Dosimetry in Radiopharmaceutical Therapyhealthy tissue. The utility and efficacy of a targeted radiotherapeutic procedure arise from the interplay between the physiological distribution of a radiopharmaceutical, the emitted particles of the associated radionuclide, the subject’s anatomy, and radiobiologic factors. The characterization of
scotoma
发表于 2025-3-27 11:29:37
http://reply.papertrans.cn/83/8209/820888/820888_34.png
chronicle
发表于 2025-3-27 16:02:03
Case Study #1: Alpha Particle Therapy of Leukemia Using 225Ac-Lintuzumabessed on acute myeloid leukemia (AML) cells. The name “actinium” is derived from the Greek . meaning “ray” or “beam,” and the decay of each actinium-225 atom produces 4 alpha (α) particles during the cascade to stable .Bi. Lintuzumab (HuM195) is a humanized immunoglobulin G (IgG) that was selected f
Exterior
发表于 2025-3-27 18:30:11
Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapycluding neuroblastoma, osteosarcoma, soft tissue sarcomas, and others. Dinutuximab (chimeric 14.18) and naxitamab (humanized 3F8 or hu3F8) are Food and Drug Administration (FDA)-approved monoclonal antibodies (mAb) that are specific for the penta-oligosaccharide epitope in GD2. Immuno-oncology, radi
很像弓]
发表于 2025-3-27 22:42:33
http://reply.papertrans.cn/83/8209/820888/820888_37.png
entrance
发表于 2025-3-28 05:08:01
http://reply.papertrans.cn/83/8209/820888/820888_38.png
受人支配
发表于 2025-3-28 08:54:33
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapyolabelled peptide designed to target receptors overexpressed on tumor cells. The most frequently employed target for PRRT in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells including neuroendocrine tumors (NETs). In this case study, we describe
打算
发表于 2025-3-28 13:22:09
Case Study #5: CXCR4-Targeted Radiotherapeuticsoendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is compose